Intellectual Product
ProKidney Streamlines Phase 3 Program to Expedite U.S. Approval of Rilparencel for Chronic Kidney Disease
ProKidney, rilparencel, chronic kidney disease, CKD, cell therapy, RMAT designation, FDA approval, Phase 3 trial
Sanofi’s Tolebrutinib Shows Mixed Results in Phase 3 MS Trials, Plans for FDA Filing Remain
Tolebrutinib, Sanofi, Multiple Sclerosis, Phase 3 Trials, FDA Filing
Future-Proofing Healthcare: Inclusive and Protective Patient Strategies
future-proofing, inclusive healthcare, patient-centered care, digital patient experience, data linkage, clinical trials, health and safety programs
Regeneron Takes Legal Action Against Sandoz to Block Eylea Biosimilar
Regeneron, Sandoz, Eylea, biosimilar, lawsuit, patent infringement
Cigna’s Express Scripts to Remove Humira from Preferred Lists in Favor of Cheaper Biosimilars
Cigna, Express Scripts, Humira, biosimilars, drug pricing, pharmaceutical industry
Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action
340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy
Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
AstraZeneca Wins Patent Infringement Case Against Pfizer, Vacates $107.5M Jury Award
AstraZeneca, Pfizer, patent infringement, jury award, US court